KdT has formed a new company to develop NGM313 in a rare disease indicationNGM Bio will receive up to $608 million in upfront and potential development, regulatory and sales milestone payments, as well as tiered royalties on net sales and equity in the new company SOUTH SAN FRANCISCO, Calif. and AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) and KdT Ventures today announced the signing of a worldwide license agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho recep ...

财联社12月17日讯，今日27股涨停，35股炸板，封板率为43%，友阿股份、益民集团5连板，日丰股份4 连板，天娱数科12天7板，粤传媒8天6板，诺邦股份7天4板，鑫科材料8天4板，上海凤凰4天3板。盘面 上，个股普跌，高位股集体退潮，全市场超4700只个股下跌，逾150只个股跌停。沪深两市全天成交额 1.51万亿，较上个交易日缩量1894亿。板块方面，足球概念、元件、白酒等少数板块上涨，影视、IP经 济、冰雪产业、零售等板块跌幅居前。截至收盘，沪指跌0.73%，深成指跌0.35%，创业板指跌0.02%。 人气及连板股分析 连板股晋级率降至15%，3板以上连板股家数降至仅剩4家。近期持续松动的高位股今日几乎全线溃败， 连板高度降至5板，连板最高标宜宾纸业止步7连板，盘中一度上演天地板，另外三维通信等多只人气股 盘中亦走出天地板。使得全天超百家非ST个股跌停，微盘股成为其中的杀跌重灾区，整个微盘股指数 跌近6%。不过上海凤凰、开开实业等部分近期低位新崛起的连板个股盘中出现尝试反核修复动作，加 上电声股份等部分20CM个股午后获得抄底资金回流一度展开快速修复，或标志着短线分歧今日出清临 近尾声。 主线热点 昨日举 ...

Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in mitochondrial DNA-driven primary mitochondrial diseases Total transaction value of approximately US$66.1 million No external funding required to fund acquisition and KL1333 development costs Pharming to host a conference call on Monday, December 16, 2024 at 14:00 CET (8:00 am EST) Leiden, t ...

In 2022, Amazon introduced the Buy with Prime button, allowing premium subscribers to make purchases using their Amazon account even when shopping on other websites.Now the company is bringing a similar concept to its cloud-computing business.At its Reinvent conference in Las Vegas on Wednesday, Amazon Web Services said a new Buy with AWS button will be available for cloud software partners to embed on their sites as a way for customers to pay.AWS is the leading provider of cloud infrastructure, ahead of Mi ...

Billionaire hedge fund manager Ken Griffin just raised Citadel's position in global-consulting powerhouse Accenture.No other company has benefited more from the artificial intelligence (AI) revolution than Nvidia. The company's compute and networking products are connected to just about every single application in generative AI in some form or fashion.Given its influence on the generational opportunity AI presents, it's not shocking to learn that investors have been eagerly buying Nvidia stock in droves ove ...

Even as consumers have experienced some continued stress from the prior period of high inflation, Walmart (WMT -1.04%) continues to be one of the biggest winners in the retail space. The retail giant posted another strong quarter of sales and took a positive view on the upcoming holiday season.The stock is now up more than 60% year to date, as of this writing. The question for investors is, can the momentum in the stock continue? Let's take a closer look at its most recent results and guidance to help find ...

“Channel Therapeutics” reflects the Company’s focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulationNew name is in advance of multiple near-term data readouts FREEHOLD, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation, (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that on November 18, 2024 it had changed its name to Channel Therapeutics Corporation (“Channel” or the “Company”) ...

Core Insights - The Phase 2 data supports the proof-of-concept for efgartigimod SC in treating myositis, leading to the decision to continue development in the Phase 3 ALKIVIA study across all three myositis subtypes [1][2] - Efgartigimod SC has the potential to be the first targeted treatment for myositis patients with limited existing options [1][2] Study Design - The ALKIVIA study is a randomized, double-blind, placebo-controlled, multicenter Phase 2/3 trial involving 240 patients, focusing on idiopathic inflammatory myopathies (IIM) across three subtypes: IMNM, ASyS, and DM [3] - The primary endpoint is the mean total improvement score (TIS) at 24 weeks for Phase 2 and 52 weeks for Phase 3, with key secondary endpoints including response rates and quality of life measures [3] Efficacy and Safety - The Phase 2 portion of the ALKIVIA study met its primary endpoint, showing a statistically significant treatment effect in mean TIS at Week 24, with improvements across all six core set measures compared to placebo [2][3] - The safety and tolerability profile of efgartigimod SC was consistent with previous clinical trials [2] Background on Myositis - Idiopathic inflammatory myopathies (myositis) are rare autoimmune diseases that can severely impact muscle function and quality of life, affecting multiple organs [4] - The classification of myositis has evolved, with new subtypes like IMNM and ASyS emerging alongside traditional classifications [4][5] About Efgartigimod SC - Efgartigimod SC is a human IgG1 antibody fragment designed to reduce pathogenic IgG antibodies by blocking the IgG recycling process, currently evaluated in over 15 severe autoimmune diseases [6] - It is the first approved FcRn blocker globally, marketed under various names for conditions like generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy [6] Company Overview - Argenx is a global immunology company focused on developing novel antibody-based medicines for severe autoimmune diseases, partnering with academic researchers to translate immunology breakthroughs into effective treatments [7]

Company Overview - Incyte has faced a setback in its mid-stage study of MRGPRX2 (INCB000262) for chronic spontaneous urticaria (CSU), leading to a pause in enrollment due to preclinical toxicology findings [1][4] - The company is collaborating with the FDA to determine the next steps following the data sharing [4] Stock Performance - Shares of Incyte declined by 9% in after-market trading on November 18 [2] - Year-to-date, Incyte's shares have increased by 5.4%, contrasting with an 11.1% decline in the industry [3] Product Pipeline - Enrollment in other proof-of-concept studies for INCB000262 is complete, and data from these studies will inform future development and potential growth of backup molecules [5] - Data from the phase II study of MRGPRX4 in cholestatic pruritus does not support further development [4] Dependence on Jakafi - Jakafi, Incyte's lead drug, is a JAK1/JAK2 inhibitor approved for multiple indications, including polycythemia vera and myelofibrosis [6] - Sales of Jakafi remain strong, but the company is heavily reliant on this drug for top-line growth [7] Competitive Landscape - Increased competition for Jakafi's indications is evident, particularly with the FDA's approval of GSK's Ojjaara for similar conditions [8] - Jakafi is expected to lose patent protection in the coming years, making the successful development of new drugs critical for Incyte [8] Market Position - Incyte currently holds a Zacks Rank of 3 (Hold) [9] - Comparatively, Immunocore Holdings and Castle Biosciences are better-ranked stocks in the biotech sector, both holding a Zacks Rank of 1 (Strong Buy) [9]

Stellantis' Ram 1500 Revolution battery-electric concept pickup truck is introduced during a keynote address by Stellantis CEO Carlos Tavaras during CES 2023 at The Venetian Resort Las Vegas on January 05, 2023 in Las Vegas, Nevada.DETROIT — Stellantis is delaying the launch of its Ram electric pickup trucks from this year until the first half of 2025, as the transatlantic automaker continues testing the vehicles.CEO Carlos Tavares on Tuesday declined to disclose details regarding what caused the delays as ...